Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte

• Published in: Joint, bone, spine : revue du rhumatisme bone, spine : revue du rhumatisme, 2020-01, Vol.87 (1), p.49-55
• Main Authors: Dumaine, Cécile, Bekkar, Sara, Belot, Alexandre, Cabrera, Natalia, Malik, Salma, von Scheven, Annette, Carbasse, Aurelia, Woerner, Andreas, Wouters, Carine, Bouayed, Kenza, Pillet, Pascal, Schroeder, Silke, Hofer, Michael, Hentgen, Véronique
• Format: Article
• Language: English
• Subjects: Adalimumab - therapeutic use; Antirheumatic Agents - adverse effects; Arthritis, Juvenile - drug therapy; Arthritis, Juvenile - epidemiology; Biological Products - adverse effects; biologics; Child; Etanercept - therapeutic use; Humans; infections; Infections - epidemiology; Juvenile Idiopathic Arthritis; Retrospective Studies
• ISSN: 1297-319X; 1778-7254
• DOI: 10.1016/j.jbspin.2019.07.011

The main objective of our study is to assess the infectious adverse events occurring in juvenile idiopathic arthritis (JIA) children treated with biological agents. Patients were selected from the retrospective module of the JIRcohorte, data concerning the period between January 2001 and August 2015. All infectious adverse events (IAE) were retrieved. For every infectious side effect, the date, the severity, the need for a hospitalization, the type of pathogen and the affected organ were noted. Incidence rates were expressed in number of events per 100 person-years (100p-y), and OR were calculated. Six hundred seventy-seven patients with JIA were included in the study. A total of 3075.4 person-years of exposure were analyzed. One hundred eighty-four infectious events were described (6.0 events/100 p-y): 15.5/100 p-y with tocilizumab (TCZ), 9.6/100 p-y with Canakinumab (CAN), 7.4/100 p-y with abatacept (ABA), 6.9/100 p-y with Golimumab (GOL), 6.7/100 p-y with Anakinra (ANA), 6.3/100 p-y with Infliximab, 4.8/100 p-y with Etanercept, and 3.7/100 p-y with Adalimumab. Risk of developing an infection was significantly higher with IL-6 antagonists or IL-1 antagonists than with TNF-inhibitor. Forty point eight percent of the infectious adverse events (IAE) affected the upper respiratory tract or the Ear, nose and throat (ENT) system. Twelve infectious adverse events were described as severe or very severe (0.4/100p-y). No case of tuberculosis or death was reported. Infectious complications with biologics occurring in children treated for JIA are rare, and in most of the cases have a mild or moderate severity, affecting mainly the upper respiratory tract or the ENT.